Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

23.66 -0.51 (-2.09%)
Delayed Quote Updated: 11:21 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Pricing of $150 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday. 
Via Benzinga
News headline image
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Arcutis Biotherapeutics Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Verizon Posts Upbeat Earnings, Joins RTX, Procter & Gamble And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mixed, with the Dow Jones index falling around 70 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Flexsteel Industries Posts Strong Preliminary Results, Joins Wipro, Sify Technologies And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗
U.S. stock futures were mixed this morning, with the Dow futures gaining around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) is One of Monday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
Why Arcutis Biotherapeutics Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket ↗
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) rose sharply in pre-market trading after the FDA approved company’s ZORYVE topical foam, 0.3% for the treatment of seborrheic dermatitis in... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Monday morning! 
Via InvestorPlace
News headline image
FDA Approves Arcutis Biotherapeutics' Lead Drug For Scaly Skin Disorder ↗
The FDA approved Arcutis Biotherapeutics Inc's (NASDAQ: ARQT) Zoryve (roflumilast) topical foam, 0.3% for seborrheic dermatitis in individuals  
Via Benzinga
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.